Top-News
Werbung
Attraktive Knock-Outs auf Dexcom Inc
Typ Hebel Bid / Ask WKN
Call
5,6 1,48 € / 1,49 €
FA0BQR
Typ Hebel Bid / Ask WKN
Put
3,4 2,15 € / 2,16 €
SY6AU2
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Dexcom Inc
Gesundheitswesen: Ausstattung u. Produkte USA

Dexcom Inc Aktie

Aktie
WKN:  A0D9T1 ISIN:  US2521311074 US-Symbol:  DXCM
84,66 $
+0,55 $
+0,65%
75,418 € 15:41:08 Uhr
Depot/Watchlist
Aktienanzahl *
397,68 Mio.
Marktkapitalisierung *
30,50 Mrd. €
Streubesitz
2,18%
KGV
54,77
Index-Zugehörigkeit
Nasdaq 100
IR-Website
zur Website
*Stand: 15.07.2024
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,55: HT4S35
Werbung

Dexcom Inc News

13.05.25 - Businesswire
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current ...
01.05.25 - Businesswire
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025.
22.04.25 - PR Newswire
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm PR Newswire
22.04.25 - Businesswire
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
DexCom, Inc . (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-​of-a-kind Name, Image and Likeness program ...
10.04.25 - Businesswire
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for ...
03.04.25 - Businesswire
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a ...
01.04.25 - Businesswire
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a ...
25.03.25 - Businesswire
Dexcom Appoints Jon Coleman as Chief Commercial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman ...
19.03.25 - Businesswire
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-​region report, the "Dexcom State of Type 2 Report: Access and ...
10.03.25 - Businesswire
Dexcom Appoints Renée Galá to Board of Directors
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025.
27.02.25 - Businesswire
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46 th Annual Raymond James Institutional Investors Conference ...
08.12.24 - Börse-Global
DexCom Aktie: Die Lage der Dinge
Die DexCom-​Aktie verzeichnete am 7. Dezember einen positiven Handelstag an der Börse. Der Kurs des Medizintechnikunternehmens stieg um 0,23 Prozent auf 73,50 Euro. Dieser ...
18.10.24 - PR Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit PR Newswire
17.10.24 - PR Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit PR Newswire
17.10.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM PR Newswire
17.10.24 - PR Newswire
DXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit
DXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit PR Newswire
17.10.24 - PR Newswire
The Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
15.10.24 - PR Newswire
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - DXCM
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - DXCM PR Newswire
15.10.24 - PR Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit PR Newswire
14.10.24 - PR Newswire
Investors who lost money on DexCom, Inc.(DXCM) should contact The Gross Law Firm about pending Class Action - DXCM
Investors who lost money on DexCom, Inc.(DXCM) should contact The Gross Law Firm about pending Class Action - DXCM PR Newswire

Newssuche

Videos

newspaper
10:01 Uhr 0,00%
Technical Trading: Die 3 besten Monate...
10yr T-Notes Long Typ: Turbo Open End WKN: NG8ZZF Hebel: 14,89 Laufzeit: OpenEnd Einstieg: Market ... Mehr »